Project Grant R01AI178885
Award Date
7/5/24
Completion Date
6/30/29
Dollars Obligated
$817K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Fort Collins, CO 80521, USA
Similar Awards
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund the development and validation of advanced imaging technologies to enable the ultrasensitive detection of Mycobacterium tuberculosis (MTB) infection. The key objectives are to:
Develop new imaging methods capable of detecting single MTB bacteria in vitro and in vivo, building upon the research team's preliminary work...
This $978,338 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a research initiative to develop an effective therapeutic vaccine for the prevention of secondary Mycobacterium tuberculosis (M.TB) infection. The research, conducted by Seattle Children's Research Institute, aims to screen 16 vaccine candidates consisting of 4 antigens and 4 adjuvants to identify optimized combinations that can...
This $1,506,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a highly-multiplexed CRISPR-based tuberculosis (TB) drug susceptibility test. The project, led by Rutgers University, leverages a CRISPR platform called CARMEN to create a simplified, accurate, and comprehensive TB drug susceptibility testing solution. Key objectives include developing assays for...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $237,288 Project Grant (R21AI185841) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Central Florida (UCF) to optimize novel inhibitors of mycolic acid synthesis as tuberculosis (TB) drug candidates.
The grant aims to address the urgent need for new antibiotic treatments for TB by building on UCF's discovery of a first-in-class series of compounds that kill Mycobacterium...
This $1,401,256 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to discover plasma-based biomarker signatures that can be used to develop point-of-care tests for tuberculosis (TB) diagnosis, severity assessment, and treatment monitoring.
The key objectives are to: 1) Identify plasma immunometabolic biomarker signatures that accurately diagnose pulmonary TB, 2) Determine the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $749,414 to The Ohio State University to support research on the role of macrophage efflux mechanisms in the pathogenesis of Mycobacterium tuberculosis. The project aims to: 1) define the role of the MDR1 efflux pump in M. tuberculosis survival within macrophages; 2) determine if targeting the MDR1 pump or its regulator HSF1 can...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit limited liability company in Austin, Texas. The purpose of this 11-month grant is to develop a stable, aerosolizable dry powder formulation of bacteriophages (D29 phages) encapsulated in polymeric microparticles for the treatment of pulmonary tuberculosis (TB) infections. The key...
This Project Grant award, with a total funding amount of $727,273, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this 5-year project is to develop a low-cost, point-of-care diagnostic tool for tuberculosis (TB) by leveraging novel approaches to rapidly and accurately profile antibody signatures associated with active TB disease. Key products to be delivered include:
A...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is supporting a $2,817,044 research program on "Systems Genetics of Tuberculosis" over 5 years. The project aims to use a mouse model system and human clinical samples to identify biological pathways influencing tuberculosis infection outcomes. Key activities include:
Leveraging genetic diversity in mouse and bacterial...
The University of California, Los Angeles (UCLA) has been awarded a $675,156 Project Grant under the National Institute of Allergy and Infectious Diseases' (NIAID) Allergy and Infectious Diseases Research (CFDA 93.855) program. The purpose of this grant is to design and develop a rapid phenotypic drug susceptibility test, termed TRE-DST, that can accurately detect antibiotic resistance in Mycobacterium tuberculosis (TB) in a cost-effective manner, particularly for resource-limited...